Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immatics N.V. (IMTX : NSDQ)
 
 • Company Description   
Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.

Number of Employees: 255

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.06 Daily Weekly Monthly
20 Day Moving Average: 156,443 shares
Shares Outstanding: 62.91 (millions)
Market Capitalization: $444.14 (millions)
Beta: 0.38
52 Week High: $16.30
52 Week Low: $5.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.75% -2.27%
12 Week -13.59% -2.88%
Year To Date -47.47% -35.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
PAUL EHRLICH-STRASSE 15
-
TUBINGEN,2M 72076
DEU
ph: 49-7071-539-7700
fax: -
None None
 
 • General Corporate Information   
Officers
Harpreet Singh - Chief Executive Officer
Peter Chambre - Chairman of the Supervisory Board
Arnd Christ - Chief Financial Officer
Cedrik Britten - Chief Medical Officer
Carsten Reinhardt - Chief Development Officer

Peer Information
Immatics N.V. (CORR.)
Immatics N.V. (RSPI)
Immatics N.V. (CGXP)
Immatics N.V. (BGEN)
Immatics N.V. (GTBP)
Immatics N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N44445109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/24/22
Share - Related Items
Shares Outstanding: 62.91
Most Recent Split Date: (:1)
Beta: 0.38
Market Capitalization: $444.14 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.21 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/24/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 15.60
Price/Cash Flow: -
Price / Sales: 10.90
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 41.18%
Sales Growth
vs. Year Ago Period: 24.40%
vs. Previous Quarter: 136.76%
ROE
03/31/22 - -
12/31/21 - -154.19
09/30/21 - -94.21
ROA
03/31/22 - -
12/31/21 - -42.88
09/30/21 - -31.88
Current Ratio
03/31/22 - -
12/31/21 - 1.60
09/30/21 - 1.68
Quick Ratio
03/31/22 - -
12/31/21 - 1.60
09/30/21 - 1.68
Operating Margin
03/31/22 - -
12/31/21 - -260.05
09/30/21 - -221.90
Net Margin
03/31/22 - -
12/31/21 - -260.05
09/30/21 - -221.24
Pre-Tax Margin
03/31/22 - -
12/31/21 - -268.49
09/30/21 - -221.93
Book Value
03/31/22 - -
12/31/21 - 0.45
09/30/21 - 0.66
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©